No Detail Found!

Prospective Study of the HCV-RNA Genotype 3a Diagnosed Patients Treated with Sofosbuvir and Peg Interferon Alpha-3

Author(s)
Taha Nazir Microbiology and Molecular Biology Research Group, Advanced Multiple Incorporation, Mississauga ON Canada.
Nida Taha Microbiology and Molecular Biology Research Group, Advanced Multiple Incorporation, Mississauga ON Canada.
Halima Sadia Faculty of Pharmacy, Jinnah University for Women, Karachi, Pakistan
Saeed-ur-Rasheed Nazir College of Pharmacy, University of Sargodha, Sargodha, Pakistan.
Abdur Rehman University of Sargodha; Director - Rehman Lab and Diagnostics, 701-A Satellite Town, Sargodha Pakistan.
Muhammad Farooq Arqam Laboratory, Ibn-e-Sina Hospital, Sargodha, Pakistan.
Misbah Sultana University College of Pharmacy, University of the Punjab, Lahore, Pakistan.
Safia Sultana Munir Shalamar medical and dental college, Lahore, Pakistan
Abstract
Background: Hepatitis C Virus (HCV) is a global health emergency. Every year, thousands of individuals suffer from HCV. HCV if not treated, may manifest severe hepatic complications, many of which have fatal outcomes. Various therapeutic strategies are currently used to eradicate the virus from the patient’s body. Treatment of the HCV patient depends largely on the genomic typing. Objectives: The aim of the present study was to assess the comparison between Sofosbuvir and Peg-Interferon alpha in patients diagnosed with HCV RNA genotype 3a. Methodology: A prospective case cohort study had been conducted in District Headquarter Hospital, Sargodha, Pakistan. Patients diagnosed with HCV genotype 3a were enrolled in the study and randomly divided into 2 groups. Group I was assigned Sofosbuvir 400 mg and group II Peg-Interferon alpha 3 million units. Both the groups were also administered ribavirin. The study was conducted for a period of 24 weeks and efficacy was determined by the decline in the viral RNA load. Results: Each group had 50 patients of which majority were males. Compared to males, females had higher viral RNA load. However, the efficacy of both the treatment drugs was similar in both the genders. Comparatively, Sofosbuvir group showed better efficacy than Peg-Interferon group with significant difference in mean HCV RNA at the end of the study (p < 0.05). Conclusion: Although, Sofosbuvir and PEG-Interferon both demonstrated efficacy in reducing the viral RNA load, Sofosbuvir is more efficacious and better tolerated in the management of HCV RNA genotype 3a infection.
Publication Details
Page(s) 124-129
DOI DOI not available
Published Journal: RADS Journal of Pharmacy & Pharmaceutical Sciences, Volume: 9, Issue: 2, Year: 2021

Request the full text from PASTIC

Keywords
Sofosbuvir, PEG Interferon alpha, genotype 3a., HCV
0

Citations

0

Downloads

27

Views